Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

February 8, 2023 4:01 PM EST

Q4 2022 total revenues were $64.5 millionFull year 2022 revenues were $254.4 millionVanda provides update on pipeline advancements and upcoming milestones

WASHINGTON, Feb. 8, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2022.

"Our strong full year 2022 commercial performance positions Vanda well towards our objectives as we pursue a number of near term regulatory filings in bipolar I... More